Tandem Diabetes Care, Inc. (TNDM)

Looking at the tape following the Q2 2026 print, the 19% single-day pop and subsequent 21% weekly gain show that the market cares far more about the narrowing net loss (down to $21.17M) and expanding gross margins (57%, up 460 bps) than a minuscule 0.1% revenue miss. Management's reaffirmation of the $1.07B to $1.09B full-year guidance provides a solid anchor for valuation expansion, especially as operating margins improve by 800 basis points YoY.

From a clinical adoption standpoint, the shift toward a pay-as-you-go pharmacy distribution model is a game-changer. Reaching 10% of U.S. sales through the pharmacy channel aligns with what we see in practice: patients prefer simplified procurement over traditional DME channels. With 40% of type 1s on pumps but only 5% of the massive 2-million-plus insulin-using type 2 population utilizing them, unlocking pharmacy access directly targets the bottleneck keeping type 2 patients from adopting advanced tech like Control-IQ and the Mobi.

We need to keep a close eye on the supply chain friction noted in the U.S. segment. While total U.S. revenues grew 5% to $179.29 million, U.S. pump revenues actually declined 3% to $83.00 million, offset entirely by a 14% climb in supplies and other revenues. Management explicitly cited infusion set constraints as a headwind. If these manufacturing or logistical bottlenecks persist, they could cap the full velocity of the pharmacy pivot rollout.

Evaluating their regulatory and pipeline catalysts, the recent 510(k) submission to the U.S. FDA combined with ongoing development for the tubeless Mobi pump positions Tandem well against competitive threats. International sales also ticked up 7% (6% in constant currency) to $75.3 million. If direct sales expansion in international markets executes alongside the domestic pharmacy pivot, top-line growth should comfortably support their reaffirmed annual revenue targets.

On our options desk, the post-earnings reaction caught several short-term bears off guard. TNDM reported a loss of 31 cents per share, beating the Zacks consensus estimate of a 34-cent loss and improving dramatically from last year's 78-cent loss. Implied volatility spiked, and the 33,000 global pump shipments (up >10% YoY and sequentially) proved that unit volume demand remains healthy despite macro noise. We're looking at structured call spreads to ride the momentum toward the upper end of their guidance range.